ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
Proteovant Therapeutics Logo

Proteovant Therapeutics

The power of protein degradation is now being realized. This innate cellular process is responsible for maintaining protein homeostasis, and we are now exploiting it to break down the proteins that cause disease. The protein degradation opportunity is immense and reaches across a broad range of disease areas in which new and enhanced treatments are needed. Development of the best, most effective medicines for patients requires extensive biology insight, medicinal chemistry experience, drug discovery expertise and cutting-edge computational tools such as artificial intelligence and machine learning. Proteovant is leveraging targeted protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases.

Quick overview

Philadelphia, United States

Founded in 2021

11-50 Employees

Startup

Additional information

Working industry

Biotechnology

Type of company

-

Ownership structure

Privately Held

Locations

1 Headquarter

Specialised areas

Biotechnology, biopharma, immunology, oncology, neurology, protein degradation

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

United States


Overall risk estimation:

Low


ESG country scores

The ESG Data of countries are based on public sources

Environment

D

Grade (A-E)

View details

Social

A

Grade (A-E)

View details

Governance

A

Grade (A-E)

View details

Headquarter of Proteovant Therapeutics

Proteovant Therapeutics operates in 1 country around the world

City: Philadelphia

State: Pennsylvania

Country: United States

Locations of Proteovant Therapeutics

Get an overview of the locations of Proteovant Therapeutics

Location

Country

State

City

Headquarter

United States

Pennsylvania

Philadelphia

Frequently asked questions (FAQ) about Proteovant Therapeutics

Some frequent questions that have been asked about Proteovant Therapeutics

The company headquarter of Proteovant Therapeutics is located in Philadelphia, Pennsylvania, United States. It's worth noting, that the company may have more locations

As of the latest available information Proteovant Therapeutics has around 11-50 employees worldwide.

Proteovant Therapeutics was founded in 2021

The company Proteovant Therapeutics has it's main focus in the industries of Biotechnology

Based on the founding year and the amount of employees the company Proteovant Therapeutics seems to be a Startup at the current state. Note that over time that status can change

Competitors of Proteovant Therapeutics

Check out some interesting alternative companies to Proteovant Therapeutics

16250 - 1st TPD Europe 2020's Logo

16250 - 1st TPD Europe 2020

London, United Kingdom

1-10 Employees

-

As the industry consolidates pipelines and heads out of a turbulent 2023 market, the targeted protein degradation engine has shown no signs of slowing. Our blossoming community of degrader experts are inspiring each other to develop medicines to address patients’ unmet medical needs. Dedicated to Progressing the Field with Groundbreaking Research.

Orum Therapeutics's Logo

Orum Therapeutics

Kazan, Russia

11-50 Employees

2016

We are pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, and thereby improve the therapeutic window of drugs. Our goal is to bring life-changing therapies to patients by combining the power of the emerging field of protein degraders with the precision of antibodies to generate a broad portfolio of highly differentiated product candidates. A portfolio of highly differentiated products combining the power of protein degraders with the precision of antibodies.

PAQ Therapeutics's Logo

PAQ Therapeutics

Cambridge, United States

1-10 Employees

2020

We are developing a new class of small molecule degradation therapies by expanding the ability to directly target and eliminate disease-causing entities beyond proteins. PAQ’s expert team of global scientists, entrepreneurs and world-class scientific advisors are committed to broadening therapeutic horizons driven by advances in autophagy.

Lycia Therapeutics's Logo

Lycia Therapeutics

San Diego, United States

11-50 Employees

2019

To that end, we are advancing an undisclosed discovery pipeline of novel LYTAC degraders toward the clinic. We are also eligible to receive over $1.6 billion in potential milestone payments based on the achievement of prespecified preclinical, development and commercial milestones, as well as tiered royalties from mid-single to low double-digits on sales resulting from the agreement. We are leveraging the flexibility of our platform to pursue targets previously considered undruggable, opening the potential for new therapeutics options for patients. We are building a stellar team, driven to pioneer breakthrough science and motivated to make a difference for patients. Protein degradation offers the potential to eliminate disease-causing proteins. The mannose-6-phosphate receptor (M6PR) is a cell-surface glycoprotein that acts as a lysosomal trafficking shuttle.

Progenra's Logo

Progenra

Malvern, United States

11-50 Employees

2002

Progenra’s mission is to leverage its expertise in the ubiquitin proteasome system, Molecular Glues and PROTAC drugs, to discover and develop novel, first in class medicines to fill unmet needs in a spectrum of therapeutic areas. Progenra’s mission is to leverage its expertise in the ubiquitin proteasome system, Molecular Glues and, PROTAC drugs to discover and develop novel, first in class medicines to fill unmet needs in a spectrum of therapeutic areas. Its UbiPro™ Drug Discovery Platform is a multi-faceted approach based on the physiological milieux in which enzymes of the ubiquitin proteasome system interact with their substrates. The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s Disease Progenra Inc, February 2023 Parkinson’s disease (PD) is the most common neurodegenerative movement disorder.

Intropic Materials's Logo

Intropic Materials

Oakland, United States

1-10 Employees

-

To fix that, we developed nanoprotectants that keep the proteins stable and active in foreign environments. We are currently working on scaling up the technology in order to bring our vision to the world. We’re starting by addressing the plastic waste problem, making self-degrading products that can be composted or perfectly recycled. From self-degrading plastics to clean manufacturing and biosensors, our platform unlocks potential for proteins. Through years of technical development and extensive communication with the plastics ecosystem, we are ready to deliver truly impactful innovation.